Long term outcome and sequelae in patients after acute thrombotic thrombo cytopenic purpura episodes

Hamostaseologie

Volumn 33, Issue 2, 2013, Pages 113-120

  Falter, T ^a   Alber, K J ^a   Scharrer, I ^a  

^a UNIVERSITY MEDICAL CENTER MAINZ   (Germany)

Author keywords

ADAMTS13 activity; Long term outcome; Neurocognitive impairment; Thrombotic thrombocytopenic purpura

Indexed keywords

ACETYLSALICYLIC ACID; AZATHIOPRINE; CORTISONE; CYCLOPHOSPHAMIDE; ERYTHROPOIETIN; FRESH FROZEN PLASMA; IMMUNOGLOBULIN G; INSULIN; LACTATE DEHYDROGENASE; PHENYTOIN; RITUXIMAB; VINCRISTINE; VON WILLEBRAND FACTOR; VON WILLEBRAND FACTOR CLEAVING PROTEINASE;

ADOLESCENT; ADULT; AGED; ANXIETY DISORDER; ARTICLE; CLINICAL ARTICLE; COGNITIVE DEFECT; COMORBIDITY; DEPRESSION; DIARRHEA; EPISTAXIS; ERYTHROCYTE CONCENTRATE; ERYTHROCYTE TRANSFUSION; FATIGUE; FEMALE; GASTROINTESTINAL INFECTION; HEADACHE; HEMATOMA; HEMOLYTIC ANEMIA; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; INSULIN TREATMENT; JAUNDICE; MALE; MEDICAL RECORD REVIEW; NAUSEA; OUTCOME ASSESSMENT; PALLOR; PARESTHESIA; PETECHIA; PLASMAPHERESIS; PREGNANCY; QUALITY OF LIFE; RELAPSE; REMISSION; RETROSPECTIVE STUDY; SPLENECTOMY; THROMBOCYTE COUNT; THROMBOTIC THROMBOCYTOPENIC PURPURA; VOMITING; WEAKNESS;

ACUTE DISEASE; ADOLESCENT; ADULT; AGED; CAUSALITY; COMORBIDITY; FEMALE; GERMANY; HUMANS; LONGITUDINAL STUDIES; MALE; MENTAL DISORDERS; MIDDLE AGED; PREVALENCE; PROGNOSIS; PURPURA, THROMBOTIC THROMBOCYTOPENIC; RENAL INSUFFICIENCY; RETROSPECTIVE STUDIES; RISK FACTORS; TREATMENT OUTCOME; YOUNG ADULT;

EID: 84881496925     PISSN: 07209355     EISSN: None     Source Type: Journal    
DOI: 10.5482/HAMO-12-11-0019     Document Type: Article

References (40)

1. Coppo P, Veyradier A. Thrombotic microangiopathies: towards a pathophysiology-based classification. Cardiovasc Hematol Disord Drug Targets 2009; 9: 36-50.
2. Lämmle B, Kremer Hovinga J, Studt JD et al. Thrombotic thrombocytopenic purpura. Hematol J 2004;5 (Suppl 3): S6-S11.
3. Furlan M, Robles R, Lämmle B. Partial purification and characterization of a protease from human plasma cleaving von Willebrand factor to fragments produced by in vivo proteolysis. Blood 1996; 87: 4223-4234.
4. Zheng X, Chung D, Takayama TK et al. Structure of von Willebrand factor-cleaving protease (ADAMTS13), a metalloprotease involved in thrombotic thrombocytopenic purpura. J Biol Chem 2001; 276: 41059-41063.
5. Tsai HM. Pathophysiology of thrombotic thrombocytopenic purpura. Int J Hematol 2010; 91: 1-19.
6. Hellmann M, Hallek M, Scharrer I. Thromboticthrombocytopenic purpura. Internist (Berl) 2010; 51: 1136, 8-44.
7. Rock GA, Shumak KH, Buskard NA et al. Comparison of plasma exchange with plasma infusion in the treatment of thrombotic thrombocytopenic purpura. Canadian Apheresis Study Group. N Engl J Med 1991; 325: 393-397.
8. Bell WR, Braine HG, Ness PM, Kickler TS. Improved survival in thrombotic thrombocytopenic purpura-hemolytic uremic syndrome. Clinical experience in 108 patients. N Engl J Med 1991; 325: 398-403.
9. Peyvandi F, Palla R, Lotta LA. Pathogenesis and treatment of acquired idiopathic thrombotic thrombocytopenic purpura. Haematologica 2010; 95: 1444-1447.
10. Amorosi EL, Ultmann JE. Thrombotic thrombocytopenic purpura: report of 16 cases and review of literature. Medicine (Baltimore) 1966; 45: 139-159.
11. George JN. How I treat patients with thrombotic thrombocytopenic purpura: 2010. Blood 2010; 116: 4060-4069.
12. Howard MA, Duvall D, Terrell DR et al. A support group for patients who have recovered from thrombotic thrombocytopenic purpura-hemolytic uremic syndrome (TTP-HUS): The six-year experience of the Oklahoma TTP-HUS Study Group. J Clin Apher 2003; 18: 16-20.
13. George JN. The thrombotic thrombocytopenic purpura and hemolytic uremic syndromes: evaluation, management, and long-term outcomes experience of the Oklahoma TTP-HUS Registry, 1989-2007. Kidney Int Suppl 2009: S52-S54.
14. Bohm M, Vigh T, Scharrer I. Evaluation and clinical application of a new method for measuring activity of von Willebrand factor-cleaving metalloprotease. Ann Hematol 2002; 81: 430-435.
15. Banno F, Kokame K, Okuda T et al. Complete deficiency in ADAMTS13 is prothrombotic, but it alone is not sufficient to cause thrombotic thrombocytopenic purpura. Blood 2006; 107: 3161-3166.
16. Fujimura Y, Matsumoto M, Isonishi A et al. Natural history of Upshaw-Schulman syndrome based on ADAMTS13 gene analysis in Japan. J Thromb Haemost 2011; 9 (Suppl 1): 283-301.
17. Fujimura Y, Matsumoto M, Kokame K et al. Pregnancy- induced thrombocytopenia and TTP, and the risk of fetal death, in Upshaw-Schulman syndrome: a series of 15 pregnancies in 9 genotyped patients. Br J Haematol 2009; 144: 742-754.
18. Furlan M, Lämmle B. Aetiology and pathogenesis of thrombotic thrombocytopenic purpura and haemolytic uraemic syndrome: the role of von Willebrand factor-cleaving protease. Best Pract Res Clin Haematol 2001; 14: 437-454.
19. Feys HB, Deckmyn H, Vanhoorelbeke K. ADAMTS13 in health and disease. Acta Haematol 2009; 121: 183-185.
20. Mannucci PM, Canciani MT, Forza I et al. Changes in health and disease of the metalloprotease that cleaves von Willebrand factor. Blood 2001; 98: 2730-2735.
21. Chauhan AK, Kisucka J, Brill A et al. ADAMTS13: a new link between thrombosis and inflammation. J Exp Med 2008; 205: 2065-2074.
22. Claus RA, Bockmeyer CL, Budde U et al. Variations in the ratio between von Willebrand factor and its cleaving protease during systemic inflammation and association with severity and prognosis of organ failure. Thromb Haemost 2009; 101: 239-247.
23. Vesely SK, George JN, Lämmle B et al. ADAMTS13 activity in thrombotic thrombocytopenic purpura-hemolytic uremic syndrome: relation to presenting features and clinical outcomes in a prospective cohort of 142 patients. Blood 2003; 102: 60-68.
24. Scully M, Yarranton H, Liesner R et al. Regional UK TTP registry: correlation with laboratory ADAMTS 13 analysis and clinical features. Br J Haematol 2008; 142: 819-826.
25. George JN, Kremer Hovinga JA, Terrell DR et al. The Oklahoma Thrombotic Thrombocytopenic Purpura-Hemolytic Uremic Syndrome Registry: the Swiss connection. Eur J Haematol 2008; 80: 277-286.
26. Hovinga JA, Vesely SK, Terrell DR et al. Survival and relapse in patients with thrombotic thrombocytopenic purpura. Blood 2010; 115: 1500-1511.
27. Kremer Hovinga JA, Studt JD, Demarmels Biasiutti F et al. Splenectomy in relapsing and plasmarefractory acquired thrombotic thrombocytopenic purpura. Haematologica 2004; 89: 320-324.
28. Aqui NA, Stein SH, Konkle BA et al. Role of splenectomy in patients with refractory or relapsed thrombotic thrombocytopenic purpura. J Clin Apher 2003; 18: 51-54.
29. Crowther MA, Heddle N, Hayward CP et al. Splenectomy done during hematologic remission to prevent relapse in patients with thrombotic thrombocytopenic purpura. Ann Intern Med 1996; 125: 294-296.
30. Allford SL, Hunt BJ, Rose P, Machin SJ. Guidelines on the diagnosis and management of the thrombotic microangiopathic haemolytic anaemias. Br J Haematol 2003; 120: 556-573.
31. Altuntas F, Aydogdu I, Kabukcu S et al. Therapeutic plasma exchange for the treatment of thrombotic thrombocytopenic purpura: a retrospective multicenter study. Transfus Apher Sci 2007; 36: 57-67.
32. Hagel S, Jantsch J, Budde U et al. Treatment of acquired thrombotic thrombocytopenic purpura (TTP) with plasma infusion plus rituximab. Thromb Haemost 2008; 100: 151-153.
33. Fakhouri F, Vernant JP, Veyradier A et al. Efficiency of curative and prophylactic treatment with rituximab in ADAMTS13-deficient thrombotic thrombocytopenic purpura: a study of 11 cases. Blood 2005; 106: 1932-1937.
34. Scully M, Starke R, Lee R et al. Successful management of pregnancy in women with a history of thrombotic thrombocytopaenic purpura. Blood Coagul Fibrinolysis 2006; 17: 459-463.
35. Schleinitz N, Ebbo M, Mazodier K et al. Rituximab as preventive therapy of a clinical relapse in TTP with ADAMTS13 inhibitor. Am J Hematol 2007; 82: 417-418.
36. Chemnitz JM, Uener J, Hallek M, Scheid C. Longterm follow-up of idiopathic thrombotic thrombocytopenic purpura treated with rituximab. Ann Hematol 2010; 89: 1029-1033.
37. Zheng XL, Kaufman RM, Goodnough LT, Sadler JE. Effect of plasma exchange on plasma ADAMTS13 metalloprotease activity, inhibitor level, and clinical outcome in patients with idiopathic and nonidiopathic thrombotic thrombocytopenic purpura. Blood 2004; 103: 4043-4049.
38. Strauss M, Pierer M, Schonknecht P. Adjustment disorders in internal medicine diseases. Internist (Berl) 2012; 53: 1271-1275.
39. Lewis QF, Lanneau MS, Mathias SD et al. Longterm deficits in health-related quality of life after recovery from thrombotic thrombocytopenic purpura. Transfusion 2009; 49: 118-124.
40. Kennedy AS, Lewis QF, Scott JG et al. Cognitive deficits after recovery from thrombotic thrombocytopenic purpura. Transfusion 2009; 49: 1092-1101.